Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...

XOMA Royalty’s CEO Owen Hughes and CIO Brad Sitko explain how royalty investing mitigates risks while expediting biotech drug development.

AI in life sciences raises various patent law considerations, including subject matter eligibility, novelty/obviousness, and sufficiency of disclosure, explains patent attorney Noah K. Tilton.

The life sciences industry is on the brink of a significant shift. Over the next few years, a historic patent cliff will reshape Big Pharma's landscape, triggering waves of talent movement between ...